Journal of gastroenterology and hepatology
-
J. Gastroenterol. Hepatol. · Apr 2013
Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
To assess the cost-effectiveness of hepatitis C virus treatment with pegylated interferon alfa-2a and ribavirin in current and former people who inject drugs (PWID). ⋯ Despite comorbidities, increased mortality, and reduced adherence, treatment of both current and former PWID is cost-effective. Our estimates fall below the unofficial Australian cost-effectiveness threshold of $AUD 50,000 per QALY for public subsidies. Scaling up treatment for PWID can be justified on purely economic grounds.